# Royalty Pharma plc (RPRX) FY2024 Q1 P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2024-01-01 to 2024-03-31
- Filing: Q1 FY2024 10-Q, filed 2024-05-09, accession number 0001802768-24-000021
- Page: https://plicit.ai/financials/rprx/fy2024-q1-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2024-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2024-01-01 through 2024-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 567,978,000 US dollars
- **Total operating expenses, net**: 641,752,000 US dollars
- **Operating (loss)/income**: negative 73,774,000 US dollars
- **Total other income, net**: 69,501,000 US dollars
- **Consolidated net (loss)/income before tax**: negative 4,273,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net (loss)/income**: negative 4,273,000 US dollars
- **Financial Royalty Assets**: 541,546,000 US dollars
- **Other Royalty Income**: 26,432,000 US dollars
- **Research and development funding expense**: 500,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: 583,600,000 US dollars
- **General and administrative expenses**: 57,652,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $4.78 M; to noncontrolling interests: −$9.05 M.